A phase II study of perifosine in androgen independent prostate cancer-Reference-Cited by-同舟云学术

A phase II study of perifosine in androgen independent prostate cancer

Published:2005-10 Issue:10 Volume:4 Page:1133-1137
ISSN:1538-4047
Container-title:Cancer Biology & Therapy
language:en
Short-container-title:Cancer Biology & Therapy

Author:

Posadas Edwin M.,Gulley James L.,Arlen Philip M.,Trout Alisa,Parnes Howard L.,Wright John,Lee Min-Jung,Chung Eun Joo,Trepel Jane B.,Sparreboom Alex,Chen Clara,Jones Elizabeth,Steinberg Seth M.,Daniels Andrew,Figg, II William,Dahut William L.

Publisher

Informa UK Limited

Subject

Cancer Research,Pharmacology,Oncology,Molecular Medicine

Link

http://www.tandfonline.com/doi/pdf/10.4161/cbt.4.10.2064

Cited by 85 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anticancer drugs acting on signaling pathways, part 2: Inhibitors of serine-threonine kinases and miscellaneous signaling pathways;Medicinal Chemistry of Anticancer Drugs;2023

2. Role of PI3K-AKT-mTOR Pathway as a Pro-Survival Signaling and Resistance-Mediating Mechanism to Therapy of Prostate Cancer;International Journal of Molecular Sciences;2021-10-14

3. Downregulation of ATXN3 Enhances the Sensitivity to AKT Inhibitors (Perifosine or MK-2206), but Decreases the Sensitivity to Chemotherapeutic Drugs (Etoposide or Cisplatin) in Neuroblastoma Cells;Frontiers in Oncology;2021-07-12

4. Deregulated PTEN/PI3K/AKT/mTOR signaling in prostate cancer: Still a potential druggable target?;Biochimica et Biophysica Acta (BBA) - Molecular Cell Research;2020-09

5. Targeting Functional Activity of AKT Has Efficacy against Aggressive Neuroblastoma;ACS Pharmacology & Translational Science;2020-01-23